TY - JOUR
T1 - Vinca alkaloid-induced cardiovascular autonomic neuropathy
AU - Roca, E.
AU - Bruera, E.
AU - Politi, P. M.
AU - Barugel, M.
AU - Cedaro, L.
AU - Carraro, S.
AU - Chacón, R. D.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 1985
Y1 - 1985
N2 - To determine the incidence of vinca alkaloid (VA)-induced cardiovascular autonomic neuropathy (CAN), neoplastic patients were studied. Thirty-three of them were receiving chemotherapy regimens including VAs, and 30 were receiving chemotherapy without VA and were considered controls. Abnormal variation in blood pressure on standing, heart rate during deep breathing, and heart rate on standing was found in 27 (82%), 16 (48%), and 16 (48%) patients receiving VA versus nine (30%; P < 0.01), three (10%; P < 0.05), and one (P < 0.001) controls, respectively. Of 198 tests performed, 100 were abnormal in patients receiving VA (51%) versus 33 of 180 tests in the controls (18%; P < 0.001). Although abnormal clinical or electrocardiographic tests for CAN appeared significantly more frequently in patients who received high doses of VA (P < 0.01), their incidence was not significantly different in patients ≥ 60 years of age, in those who received doxorubicin, or in those who showed abnormal deep tendon reflexes. The consequences of VA-induced CAN might be especially important for potentially curable cancer patients.
AB - To determine the incidence of vinca alkaloid (VA)-induced cardiovascular autonomic neuropathy (CAN), neoplastic patients were studied. Thirty-three of them were receiving chemotherapy regimens including VAs, and 30 were receiving chemotherapy without VA and were considered controls. Abnormal variation in blood pressure on standing, heart rate during deep breathing, and heart rate on standing was found in 27 (82%), 16 (48%), and 16 (48%) patients receiving VA versus nine (30%; P < 0.01), three (10%; P < 0.05), and one (P < 0.001) controls, respectively. Of 198 tests performed, 100 were abnormal in patients receiving VA (51%) versus 33 of 180 tests in the controls (18%; P < 0.001). Although abnormal clinical or electrocardiographic tests for CAN appeared significantly more frequently in patients who received high doses of VA (P < 0.01), their incidence was not significantly different in patients ≥ 60 years of age, in those who received doxorubicin, or in those who showed abnormal deep tendon reflexes. The consequences of VA-induced CAN might be especially important for potentially curable cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=0022000879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022000879&partnerID=8YFLogxK
M3 - Article
C2 - 3971390
AN - SCOPUS:0022000879
SN - 0361-5960
VL - 69
SP - 149
EP - 151
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 2
ER -